Fluidic Analytics raises $31m to launch new lab tools and unlock biology behind major diseases5 Dec 2018
The financing will power the global commercial launch of the company's Fluidity One system.
Fluidic Analytics has raised $31 million to continue developing its transformational products for characterising proteins and their behaviour. The proceeds of the financing will be used to continue the commercial roll-out of the company’s lab-tools pipeline and to develop further high-value clinical applications of its technology.
Proteins and their behaviour are crucial to understanding how diseases develop, identifying the way that drugs interact with their targets, and developing new methods for matching the right treatment to the right patient at the right time. DNA gives clues about what is likely to happen over a lifetime. Proteins and their behaviour tell us what is actually happening now. To date, the emergence of a deep understanding of the biology underlying disease and health in real time has been hampered by the shortcomings of existing tools for protein characterisation.
Fluidic Analytics’ products are based on a proprietary technology platform from the University of Cambridge. This platform was designed explicitly to give deep insights into the way that proteins fold, aggregate and interact by characterising them in solution – precisely as they exist in the body. These products have the potential to help researchers understand the mechanisms underlying conditions like Alzheimer’s disease, pharmaceutical companies develop more effective drugs, and patients gain access to more accurate diagnostics in the clinic, at the pharmacy or even at home.
“This financing will power the global commercial launch of our Fluidity One system and enable our team to bring our next two lab-tools products to market. It will also allow us to advance a number of high-potential clinical applications that could help us make an even bigger impact on the world. We are delighted to be working with investors who share our vision of helping people everywhere make better decisions about how diseases are diagnosed, treatments are developed, and personal well-being is maintained,” said Andrew Lynn, CEO, Fluidic Analytics.
“We are always looking for the brightest thinkers with the best teams and technology to back for the long-term, and we have found that in Fluidic Analytics. The progress that Fluidic has made to date has been exemplary. As we enter the century of biology, the world needs transformational technologies that can help us understand the full picture of how biology unfolds in daily life and we are delighted to be backing a company that is doing just that,” said Vishal Gulati, Healthtech VC, Draper Esprit.
Tim Rea, Investor, BGF, commented: “The team at Fluidic Analytics have built a potentially life-changing technology and brought their idea from concept to production in an incredibly short time. The market for pharmaceutical tools and technology is thriving and Fluidic Analytics has created products for which there is growing demand. We’re excited to be supporting the team as they scale up and take advantage of the significant opportunity to develop this critical technology further."
WuXi AppTec expands site in California for pharmaceutical R&D services
13 Dec 2018
Expanded facility will establish a center of excellence in screening, discovery biology, pharmacology, and small molecule process R&D including Phase I GMP manufacturing.Read more
Cambrex expands analytical capabilities
12 Dec 2018
The $1 million investment will assist in getting new products to commercial launch faster.Read more
MIT engineers repurpose wasp venom as an antibiotic drug
9 Dec 2018
Altered peptides from a South American wasp’s venom can kill bacteria but are nontoxic to human cells.Read more
Spanish CDMO working ahead of EU serialisation deadline
6 Dec 2018
Company now able to serialise commercial batches manufactured by them for clients; it can also offer standalone serialisation services as an outsourcing partner.Read more
OnDosis and Recipharm partner to advance a novel treatment regimen for ADHD
4 Dec 2018
The new treatment will leverage OnDosis’ proprietary technology, which integrates oral drugs in form of micro units and individualised dosing, in a handheld device.Read more
NIH to evaluate effectiveness of male contraceptive skin gel
28 Nov 2018
The gel formulation includes the progestin compound segesterone acetate, in combination with testosterone, and is applied to the back and shoulders and absorbed through the skin.Read more
QPS expands US-based Phase I clinical trial capabilities
27 Nov 2018
Expansion supports the growing needs of the company's pharmaceutical, biotechnology and CRO partners.Read more
Grant winners to investigate continuous manufacturing for gene therapies
26 Nov 2018
Cobra Biologics, Pall, and the Cell and Gene Therapy Catapult share £1.5 million grant from the UK's innovation agency.Read more
Proprietary nasal delivery formulation of diazepam reaches NDA
7 Nov 2018
The absolute bioavailability of the Valtoco intranasal formulation was 96% of intravenous diazepam in a Phase I cross-over trial.Read more
Plasticell receives EU funding to advance neurodegenerative disease research
1 Nov 2018
Th company's CombiCult combinatorial cell culture technology will be used to generate high fidelity, progenitor and terminally differentiated neuronal and glial cell subtypes for incorporation into next-generation models.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation